Paxlovid rebound. Tested negative for four days after completion of medication, then began testing positive again and had symptoms again; COVID-19 treated with Paxlovid; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Paxlovid rebound. Tested negative for four days after completion of medication, then began testing positive again and had symptoms again) and COVID-19 (COVID-19 treated with Paxlovid) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Allergy to unknown drug.). Concomitant products included BUPROPION HYDROCHLORIDE (WELLBUTRIN) and ETHINYLESTRADIOL, ETONOGESTREL (ELURYNG) for an unknown indication.    On 03-Nov-2021 at 12:00 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2022, the patient experienced COVID-19 (COVID-19 treated with Paxlovid). On 20-May-2022 at 9:00 PM, the patient experienced COVID-19 (Paxlovid rebound. Tested negative for four days after completion of medication, then began testing positive again and had symptoms again). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 10-May-2022 to 15-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Paxlovid rebound. Tested negative for four days after completion of medication, then began testing positive again and had symptoms again) had not resolved and COVID-19 (COVID-19 treated with Paxlovid) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: negative (Negative) Tested negative for four days after completion of medication. On 20-May-2022, SARS-CoV-2 test: positive (Positive) Then began testing positive again and had symptoms again.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient tested negative for four days after completion of Paxlovid then began testing positive again and had symptoms again.  Company Comment: This is a spontaneous case concerning a 33-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19 (reported as COVID-19 and COVID-19 recurrent), which occurred approximately 6 months after receiving a dose of mRNA-1273 vaccine (no information disclosed on previous COVID-19 vaccinations). The initial infection of COVID-19 was treated with Paxlovid for 6 days. After treatment of Paxlovid, patient had a negative SARS-CoV-2 test for four days. The next day, patient started to have unspecified symptoms and tested positive for COVID-19. Patient reported that the event COVID-19 recurrent was not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 33-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19 (reported as COVID-19 and COVID-19 recurrent), which occurred approximately 6 months after receiving a dose of mRNA-1273 vaccine (no information disclosed on previous COVID-19 vaccinations). The initial infection of COVID-19 was treated with Paxlovid for 6 days. After treatment of Paxlovid, patient had a negative SARS-CoV-2 test for four days. The next day, patient started to have unspecified symptoms and tested positive for COVID-19. Patient reported that the event COVID-19 recurrent was not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.